Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

  • Jazz Pharmaceuticals plc JAZZ has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's HOWL WTX-613.
  • WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule.
  • "We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumors, and thereby expanding its clinical utility in treating cancer," said Rob Iannone, executive vice president, global head of R&D of Jazz Pharmaceuticals
  • "We are excited about the potential of WTX-613 based on compelling proof-of-concept data, recently presented at ASH, where a WTX-613 surrogate molecule demonstrated anti-tumor activity in preclinical models," Iannone added.
  • WTX-613 is currently in preclinical development. Jazz expects to submit an Investigational New Drug (IND) application to the FDA for WTX-613 in 2023.
  • Jazz will make an upfront payment of $15 million to Werewolf, and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26 billion. 
  • Pending approval, Werewolf is eligible to receive a tiered, mid-single-digit percentage royalty on net sales of WTX-613.
  • Price Action: HOWL shares are up 9.94% at $5.20 during the premarket session on the last check Thursday.

Posted In: Briefswhy it's movingBiotechNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.